A phase II clinical trial, entitled “Nogo Inhibition in Spinal Cord Injury” (NISCI–NCT03935321), began in 2019 to test the efficacy of the anti-Nogo-A antibody treatment after SCI in severely injured paraplegic and tetraplegic patients [230]. This evidence concerns the gene RTN4 and spinal cord injury.